UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than ...

A new study reveals that changes in gut microbial load, influenced by factors like diet, age, and antibiotics, drive the presence of bacteria previously linked to diseases such as inflammatory bowel ...

FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter2024 to Discussthe Design of aCM-101 Accelerated Approval Phase 3Trial in Primary ...

They selected one random outpatient visit per person from 2007 to 2020, collecting information such as age, sex, race, body ...

Non-invasive biomarkers will be assessed as part of the secondary endpoints, with no liver biopsy endpoint. The Phase 3 program is designed to comprise a minimum of 1,800 patients exposed to ...

COLUMBIA, Mo. (KY3) - A new form of diagnostic imaging is changing how doctors see and treat lung conditions like cystic ...

The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US ...

Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...

The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US Food and Drug ...

Fountain Life, a longevity, preventative health, advanced diagnostics, and therapeutics company, today announced that it has ...